BioSyent Inc. (CVE:RX – Get Free Report)’s stock price reached a new 52-week high during trading on Tuesday . The stock traded as high as C$16.58 and last traded at C$16.79, with a volume of 17273 shares traded. The stock had previously closed at C$16.00.
BioSyent Price Performance
The stock has a market cap of C$189.88 million, a P/E ratio of 19.66 and a beta of 1.11. The company’s 50 day moving average price is C$15.26 and its 200-day moving average price is C$14.82. The company has a quick ratio of 6.91, a current ratio of 2.07 and a debt-to-equity ratio of 6.85.
Insider Buying and Selling
In other BioSyent news, Director Seyed Ahmad Ashrafi sold 1,884 shares of the company’s stock in a transaction on Tuesday, June 30th. The shares were sold at an average price of C$14.65, for a total transaction of C$27,600.60. Following the transaction, the director owned 37,261 shares in the company, valued at approximately C$545,873.65. This represents a 4.81% decrease in their ownership of the stock. Insiders sold a total of 5,635 shares of company stock valued at $85,368 over the last ninety days. Company insiders own 33.65% of the company’s stock.
BioSyent Company Profile
BioSyent Inc, together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia. It offers Tibella, a hormone replacement therapy consisting of tibolone; Inofolic, a natural health product to address polycystic ovarian syndrome symptoms; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by aging, menopause, stress, and chemotherapy; and Gelclair, a gel formulated to aid the pain or oral mucositis.
See Also
- Five stocks we like better than BioSyent
- Is the Fed Playing Chess With Rates—Or Just Behind the Curve Again?
- IonQ’s AI Breakthrough Looks Big—But Can It Drive Revenue?
- Broadcom CEO Holds $350B Outlook Strong Amid Calls to Slow Froniter AI Development
- Microsoft’s 8% Dividend Hike: Confidence Signal or Distraction From Capex Math?
Receive News & Ratings for BioSyent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioSyent and related companies with MarketBeat.com's FREE daily email newsletter.
